Type 2 diabetes mellitus (T2DM), which affects 29 million Americans, is a major risk factor for the development of cardiovascular diseases (CVD) such as myocardial infarction and heart failure (HF). In the last decade, empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, has emerged as a novel and promising drug for T2DM patients with benefits extending beyond its glucose-lowering action [1] . These comprise weight loss, blood pressure reduction, lessening arterial stiffness, and a remarkable drop in cardiovascular death [2] [3] [4] [5] . This drug elicits its glucose-lowering effect by inhibiting SGLT-2, thereby decreasing glucose reabsorption in the proximal tubule and increasing glucose excretion in the urine [6] . While the glucose-lowering effect of empagliflozin is well recognized, the cardiovascular benefits were unexpected. The first study that reported the protective role of empagliflozin on cardiovascular outcomes was the EMPA-REG OUTCOME trial, which included 7020 T2DM patients from 42 countries with a high risk of cardiovascular events [3] . Enrolled subjects received either empagliflozin once daily (10 or 25 mg) or placebo in addition to standard care. Surprisingly, a significant reduction in death from cardiovascular cause, hospitalization from heart failure, and percent of death from any cause were noticed in the case of patients receiving empagliflozin. Subsequently, several other clinical trials confirmed the cardiac benefits of empagliflozin in patients with or without baseline heart failure [4, 5] . Kaku et al. [5] investigated the potential cardiovascular benefits of empagliflozin treatment in the Asian population. Indeed, T2DM patients receiving empagliflozin showed significantly reduced cardiovascular associated events. While the available data provide a strong evidence of empagliflozin benefits in reducing cardiac mortality and morbidity, the mechanism through which empagliflozin exerts its cardiac benefits is unknown. Therefore, an important challenge remaining is to elucidate the molecular mechanism of empagliflozin-mediated cardiac benefits.
The study by Hammoudi et al. [7] in this issue of Cardiovascular Drugs and Therapy examined the underlying signaling mechanism of empagliflozin-mediated cardiac benefits in a mouse model of T2DM. Hammoudi et al. employed a comparatively simple study design with three experimental groups: the first group included lean mice ob/ob which served as controls, the second group included ob/ob mice that were fed a diet containing vehicle, and the third group included ob/ ob mice fed with a diet mixed with empagliflozin (10 mg/kg/ day) for 6 weeks. Empagliflozin treatment significantly lowered HbA1c, improved diastolic function (reduced E velocity and deceleration time), and increased left ventricle compliance (increased end diastolic pressure-volume relationship). While there were no alterations in the systolic function at steady state, dobutamine-induced response was significantly improved with empagliflozin treatment. These observations confirm that the employed preclinical model in the present study accurately recapitulates the clinical findings with human trials. However, a particular strength of the study is the elucidation of the underlying molecular mechanisms, specifically, identification of several intrinsic pathways potentially mediating the favorable cardiac outcome (Fig. 1) .
Impaired cardiac contractility and relaxation are often associated with dysregulated sarcoplasmic reticulum (SR) Ca 2 + homeostasis. Therefore, Hammoudi et al. [7] tested the hypothesis that molecular machinery regulating diastolic Ca 2 + levels, such as phospholamban (PLB) phosphorylation or SERCA2a expression, may act as downstream targets of empagliflozin. While SERCA2a expression was comparable between the groups, empagliflozin treatment led to significantly increased phosphorylation of PLB at both PLB-Ser 16 and PLB-Thr 17 , supporting the notion that increased phospholamban activity augments the SERCA2a function leading to an improved diastolic function. However, it is not clear if empagliflozin effects on the cardiac contractility and Ca + handling are direct or a secondary outcome of overall improved metabolic effects. Further contractility experiments with isolated adult cardiomyocytes and patch clamping studies are required to address this issue. Nevertheless, considering the fact that there is no approved drug to specifically target the heart failure with preserved ejection fraction (HFpEF), the implication of these finding is enormous.
At the molecular level, empagliflozin treatment significantly blunted the activation of mitogenic stress pathways such as ERKs, JNKs, and p38 MAPKs (Fig. 1) . Importantly, all these signaling cascades are strongly implicated in the pathological cardiac hypertrophy and heart failure. However, Hammoudi et al. [7] the first to identify that empagliflozin may exert its cardiac benefits by blunting the activation of MAPKs. As pointed out earlier, direct studies with isolated cardiomyocytes are needed to further confirm the effect of empagliflozin on the regulation of MAPK signaling in the heart. Since AKT (protein kinase B) activity plays a dynamic role in influencing both survival and ventricular contractile performance, Hammoudi et al. tested the hypothesis that cardiac AKT activity may be modulated by empagliflozin. Indeed, AKT activity was found to be preserved by empagliflozin treatment, which is known to augment the cardiomyocyte survival and contractility. Thus, Hammoudi et al were the first to identify several novel intrinsic cardiac pathways which may contribute to the observed favorable cardiac outcome of the empagliflozin treatment. Clearly, many of these findings are preliminary, proposing multiple exciting hypotheses, and needs further investigation. In agreement with the present study, numerous in vivo studies using different rodent models of diabetes have demonstrated the beneficial effect of SGLT-2 inhibition on adverse cardiac remodeling and ventricular function [8] [9] [10] [11] [12] [13] . However, most of the previous studies were descriptive in nature and do not provide mechanistic insight into (Table 1) . Thus, this study is an important step forward in understanding the mechanism through which this class of drugs is eliciting cardiovascular benefits. However, as the authors point out, there are several limitations to the study that need to be addressed in the future work.
Multiple mechanisms have been proposed to explain the cardiac benefits of empagliflozin; these include reduced glucose, reduced plasma volume, sodium depletion, reduced blood pressure, and reduced arterial stiffness. However, all these proposed mechanisms are primarily speculation and need further clinical and experimental evidence for validation. A recent study examined the relative expression of SGLT2 and SGLT1, the two most relevant members of the SGLT family, in normal, ischemic, and hypertrophic human hearts [14] . Consistent with previous reports, Di Franco et al. [14] reported that SGLT2 does not express in either healthy or failing (ischemic/hypertrophic) human heart. However, a high-level of SGLT1 expression is seen in control hearts. Furthermore, SGLT1 expression was significantly increased in injured heart, suggesting that increased expression of SGLT1 in cardiomyocytes may represent a potential target for empagliflozin and provides another possible explanation for the observed cardiovascular effects of empagliflozin treatment. This hypothesis can be easily tested by employing cardiac-specific SGLT1 KO animals. In order to determine whether observed benefits in the previous studies were a class effect, the CVD-REAL study compared the numbers of hospitalization due to heart failure and death in patients treated with various SGLT-2 inhibitors (dapagliflozin, canagliflozin, and empagliflozin) versus other glucose-lowering drugs (oGLDs). Consistent with the findings in the EMPA-REG OUTCOME trial, Kosiborod et al. [15] reported a reduction in hospitalization for heart failure, reduction in all-cause death, and composite reduction in hospitalization for heart failure or death, suggesting that the benefits observed in the EMPA-REG OUTCOME trial are class-related. The ongoing REFORM trial [16] will further test this hypothesis, which is a phase IV randomized, double blind trial, designed to test the efficacy of the SLGT2 inhibitor, dapagliflozin, on diabetic patients with established HF. Importantly, this critical trial will determine if SGLT2 inhibition with dapagliflozin produces Table 1 Preclinical and clinical studies demonstrating the association of SGLT inhibition and favorable cardiac outcome
Type of investigation Summary of findings Reference Clinical
In the EMPA-REG trial, patients with T2D at high risk for cardiovascular events received empagliflozin had significantly lower rates of the adverse cardiovascular events, all-cause death, and hospitalization compared to placebo group (standard care).
[3]
Clinical In a cohort of T2D with high cardiovascular risk, empagliflozin reduced heart failure (HF) hospitalization and cardiovascular death in patients with and without baseline HF.
[4]
Clinical
In this clinical investigation, the findings of the EMPA-REG trial were further verified in the Asian race. Reductions in the CV outcomes and mortality with empagliflozin were consistent with the overall findings of the EMPA-REG trial.
[5]
Preclinical (rat and rabbit) Effect of empagliflozin on cardiac Na ] m via inhibition of the cardiac NHE. [8] Preclinical (rats with metabolic syndrome)
Empagliflozin treatment improved cardiac inflammation, oxidative stress, hypertrophy, and fibrosis.
[9]
Preclinical (diabetic mouse) Dapagliflozin treatment prevented the development of hypertrophic cardiomyopathy. [10] Preclinical (db/db mice) Empagliflozin preserves the myocardial ultrastructure and improves cardiac hypertrophy, fibrosis, and diastolic dysfunction.
[11]
Preclinical (zebrafish) Empagliflozin treatment or knockdown of SGLT2 attenuates aristolochic acid (AA)-induced heart failure in developing zebrafish embryos.
[12]
Preclinical (ob/ob mice) SGLT-2 inhibition with dapagliflozin reduces the cardiac inflammation and attenuates the development of diabetic cardiomyopathy in mice with T2D.
[13]
Translational The relative expression of SGLT2 and SGLT1 was determined in healthy, ischemic, and hypertrophic human hearts. SGLT2 does not express in the human heart either in normal or pathological conditions. Whereas SGLT1 expresses in healthy heart and significantly upregulated in the diseased heart.
[14]
In the CVD-REAL trial, patients treated with SGLT-2 inhibitors had lower risk of heart failure and death versus other glucose-lowering drugs, suggesting that the benefits observed in the EMPA-REG trial may be a class effect.
[15]
The ongoing REFORM trial is a phase IV randomized, double blind, placebo controlled trial, designed to test the efficacy of the SLGT2 inhibitor, dapagliflozin, on diabetic patients with known HF. REFORM trial identifier: https://clinicaltrials.gov/show/NCT02397421.
[16]
Meta-analysis The meta-analysis data suggest that SGLT2 inhibition leads to an overall protection against cardiovascular outcomes and death. [17] similar beneficial effects in patients with established HF as seen with empagliflozin in the EMPA-REG trial. Finally, a recent meta-analysis of six regulatory submissions and multiple trials with seven different SGLT-2 inhibitors confirmed the benefits of SGLT-2 inhibitors in T2DM patients against cardiovascular outcomes and mortality [17] . Additional clinical studies are urgently needed to define potential roles of empagliflozin in HFpEF patients. In summary, this study, for the first time, provides mechanistic insight into the empagliflozin-mediated cardiac benefits; preclinical models have been optimized; signaling pathways have been identified; and only time will tell if empagliflozin is the way we should be marching for the HFpEF treatment.
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